Canaan Leads Seed Round to Further Scale AI Agents, Already Serving 100+ Companies

NEW YORK, Jan. 28, 2025 — WiseLayer (wiselayer.com), the AI fintech company that makes AI-powered digital workers for finance and accounting teams, today announced $7.2 million in funding. The round was led by Canaan Partners, with participation from K5 Global, The Fintech Fund, Unpopular Ventures, and industry angels.

The funding will fuel the continued development of WiseLayer’s task-specific AI workers, each of whom automates a highly-manual complex recurring process performed by finance & accounting teams. The company’s current digital workforce includes:

• Angela, the AI agent for Accruals & Rev Rec (hire her at www.accruals.ai)
• Dennis, the AI agent for Discrepancies & Financial Anomalies (hire him at www.discrepancies.ai)
• … with the 4 newest AI agents each specializing in the following tasks: (1) bank reconciliations, (2) fixed asset depreciation & amortization, (3) lease accounting, and (4) prepaid expenses.

More than 100 companies currently use WiseLayer’s AI workers, including mid-sized firms & public companies.

“The exceptional early traction that WiseLayer has achieved with its many large customers, each of whom love their product, demonstrates a clear market need,” said Brendan Dickinson, general partner at Canaan Partners. “We’re thrilled to support WiseLayer’s next phase of growth as they enhance their AI-powered digital workforce for finance and accounting teams.”

“Finance & accounting teams have some of the most brilliant people at any company, yet their brainpower is often spent on recurring administrative and compliance tasks like accruals, rev rec, and more,” said Josh Stein, CEO & co-founder of WiseLayer. “WiseLayer’s mission is to build AI agents to automate these repetitive, laborious processes with precision, so that these highly-skilled people can focus on strategic financial initiatives that drive company growth.”

WiseLayer was founded by industry veterans to help finance & accounting departments solve the ever-increasing requirements with financial accuracy and compliance. It’s common for these teams to use multiple different software tools for various crucial tasks, which leads to issues with manual data extraction, data accuracy, and compliance. WiseLayer is the only AI platform that plugs into each of these tools (300+ integrations into every major ERP, billing, P2P, HRIS and more), consolidates the data, and automates time-consuming tasks like accruals, revenue recognition, financial discrepancy detection, and more.

“What makes WiseLayer wholly unique is our focus on creating specialized digital workers that each perform a specific time-consuming financial function – with unprecedented accuracy and efficiency,” said Vik Bellapravalu, CTO & co-founder at WiseLayer. “For example, if you’re a controller at a company, you can use Angela, the AI Agent for Accruals & Rev Rec to reduce your month-end accrual process from days to about an hour.”

“Today, Angela automates about 90% of a company’s accrual process. With our novel & secure AI, we’ll get that to about 98% this year,” said Jack Gillette, Head of Product & Founding Engineer.

The new funding will be used to further delight both new and existing clients by making WiseLayer’s AI workers even more efficient – and developing new AI workers, too. Additionally, the financing will be used to expand customer support infrastructure and drive market expansion.

About WiseLayer

WiseLayer makes AI-powered digital workers for finance and accounting teams. Its digital workers include Angela for Accruals & Rev Rec, Dennis for Discrepancies & Financial Anomalies, and more AI agents who specialize in additional tasks. Founded in 2022, the company is headquartered in New York City and serves finance & accounting teams across multiple industries. More than 100 companies currently use WiseLayer’s AI workers, including mid-sized firms & public companies.

CONTACT: [email protected]

SOURCE WiseLayer

Appointment of Former OurCrowd Principal will Drive Venture Builder and Fund’s Portfolio Growth and Strengthen Strategic Partnerships

HERZLIYA, Israel, Jan. 28, 2025 — Corundum Neuroscience (CNS), a leading neuroscience venture builder and fund, today announced the appointment of Itsik Francis, PhD, as Head of Business Development. The appointment comes as the company continues to expand its portfolio of neurotech ventures and strategic partnerships.

With more than 15 years of experience spanning investment and business development in the medtech and biotech sectors, Francis will focus on driving deal flow and investment strategies to propel Corundum Neuroscience’s portfolio growth. He will also provide targeted support to portfolio companies, ensuring access to vital resources and expertise. In addition, Francis will lead initiatives to strengthen and expand Corundum Neuroscience’s collaborations with key stakeholders, including medtech, medical device, and digital health companies, as well as research institutions and industry leaders worldwide.

“Corundum Neuroscience is at the forefront of advancing neuroscience solutions, and Itsik’s strategic insight and industry expertise will be instrumental in shaping our next phase of growth,” said Yasushi Yamamoto, CEO and Founder of Corundum Corp. “His proven track record in medtech investment and business development makes him a valuable addition to our leadership team as we continue to build and scale transformative neurotechnology ventures.”

Prior to joining Corundum Neuroscience, Francis served as Principal at OurCrowd, where he led key investments and contributed to the launch of the Global Health Equity Fund in partnership with the WHO Foundation. He previously held leadership roles at Medison Pharma Ventures, where he managed strategic alliances and innovation initiatives, and at Ariel Scientific Innovations, where he directed business development efforts. Francis is also the co-founder and former CEO of Citta Pharmaceuticals, a neuro-focused biotech startup. He earned his PhD in Medical Molecular Biology from University College London and conducted postdoctoral research at Columbia University Medical Center, focusing on Alzheimer’s Disease drug discovery.

“I’m excited to join Corundum Neuroscience at such a pivotal time for the neurotech space,” said Itsik Francis. “The CNS vision of translating cutting-edge science into real-world impact resonates deeply with me and I look forward to working with the team to drive new opportunities, strengthen industry collaborations, and support the growth of the firm’s portfolio of ventures.”

About Corundum Neuroscience

Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track-record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people’s health, longevity and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023, and is headquartered in Herzliya, Israel.

For company updates and information, follow Corundum Neuroscience on LinkedIn or visit: https://cnsfund.com.

Media Contact:
Danny Sudwarts
FINN Partners for Corundum Neuroscience
[email protected]
(+1) 469-297-2515

SOURCE Corundum Neuroscience

• Atalanta Therapeutics is pioneering RNA interference (RNAi) for the treatment of neurological diseases, having developed a proprietary platform that, for the first time enables RNAi to be deployed as a therapeutic approach throughout the brain and spinal cord
• The USD 75 million Series B financing will support Phase 1 clinical trials of the company’s investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s disease
• EQT Life Sciences is leading the round investing from its LSP Dementia Fund, which is co-led by Sanofi Ventures with further participation from RiverVest Venture Partners, abrdn, Inc., Mirae Asset Financial Group and F-Prime Capital

STOCKHOLM, Jan. 28, 2025 — EQT is pleased to announce that EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics (“Atalanta” or “the Company”). Atalanta, a biotechnology company based in Boston, USA, is at the forefront of using RNA interference (RNAi) to treat neurological diseases.

RNA is a molecule that carries genetic instructions from DNA, guiding cells in protein production and serving as a blueprint for cellular processes. RNAi is a method of altering these instructions, allowing the targeting of diseases at the molecular level by potentially silencing harmful genes. Atalanta has developed a proprietary RNAi platform called di-siRNA, which, for the first time, enables RNAi to be deployed as a therapeutic approach throughout the brain and spinal cord. With this new funding, Atalanta aims to advance its investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s disease to Phase 1 clinical trials.

Alicia Secor, M.B.A., Atalanta’s President and Chief Executive Officer, said: “We’re excited by the support we’ve received from this strong group of investors, led by EQT Life Sciences. This Series B will support a path to the clinic for two programs for serious neurological diseases that today lack disease-modifying therapies: KCNT1-related epilepsy and Huntington’s disease. We’re diligently progressing these medicines toward IND submissions next year so that we can start our Phase 1 trials and reach patients who are waiting.”

“Atalanta’s di-siRNA technology has shown promising ability to durably and evenly silence disease-promoting genes throughout previously inaccessible regions of the brain and spinal cord – opening a wide range of treatment possibilities for devastating neurological diseases,” said Arno de Wilde, M.D., Ph.D., M.B.A., Managing Director at EQT Life Sciences. “EQT is proud to lead this investment in Atalanta’s future as part of such a high-quality investor syndicate, and we look forward to partnering with Alicia and Atalanta’s leadership to support their continued success.”

Alongside EQT Life Sciences, the financing was co-led by Sanofi Ventures, with participation from other new investors RiverVest Venture Partners, abrdn, Inc., Mirae Asset Financial Group and existing investor F-Prime Capital. The Series B financing brings Atalanta’s total capital generated to date from financings and partnerships with Genentech and Biogen to USD 240 million.

For more information, please contact:
EQT Press Office, [email protected] 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-life-sciences-leads-usd-75-million-series-b-in-atalanta-therapeutics–a-biotech-firm-developing-,c4096665

The following files are available for download:

Topical LUT014 Treats EGFRi (Epidermal Growth Factor Receptor Inhibitor) Induced Acneiform Rash, Potentially Improving The Treatment’s Efficacy And Patients’ Quality of Life

TEL AVIV, Israel, Jan. 28, 2025 — Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, today announced that it has secured a $30 million financing to advance the development of LUT014, an innovative topically applied gel aimed at reducing EGFRi-induced rashes, a common adverse side effect of these cancer-fighting therapies. The round was led by Columbus Venture Partners and Pontifax Venture Capital, an existing investor, with Peregrine Ventures and aMoon Fund also participating.

While EGFRi therapies are highly effective for the treatment of cancer, they have dose-limiting skin toxicities, leading to substantial discontinuation of patients’ treatment in less than three months due to intolerable acneiform rashes. LUT014, a novel B-Raf inhibitor, is used for patients who develop dose-limiting rashes, potentially allowing them to continue EGFRi treatment with an improved quality of life.

“We are grateful to these investors who recognize the potential of LUT014 to address the significant unmet need caused by the toxicity of EGFRi therapies, which are otherwise effective therapeutic regimens. This financing will enable us to continue the clinical development of LUT014 with the goal of treating the acneiform rash to improve life quality and enabling adherence to EGFRi therapies,” stated Noa Shelach, Ph.D., Chief Executive Officer of Lutris Pharma. “The development and ultimate commercialization of LUT014 aligns with our mission to improve anti-cancer therapy effectiveness and to meaningfully impact the quality of life for patients.”

In October 2024, Lutris successfully completed enrollment in the international phase 2 trial of LUT014 in patients with metastatic colorectal cancer (mCRC) treated with EGFRi therapy who develop dose-limiting acneiform rash. The company expects to report top-line results from this trial during the first half of 2025 at a major medical meeting.

“Based on the broad use of EGFRi’s to treat cancer and the dermal toxicity that often emerges, many of these patients do not receive the optimal treatment against their cancer, either due to dose reduction or outright discontinuation in response to the intolerable dermal toxicity,” stated Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma. “Despite extensive research efforts in the past, no standard of care has emerged to deal with this prevalent issue, leading to a significant unmet medical need. By reversing the inhibitory effect of EGFRi therapy on downstream signaling in the skin cells, we believe that LUT014 has the potential to become an important therapeutic for EGFR inhibitor induced skin toxicity and can have a tremendous impact for patients who currently have no other effective treatment options.”

“Acneiform rash is the most common side effect of EGFRi therapies, with up to 90% of patients experiencing an adverse dermatologic event, taking a toll which can be detrimental to their therapy. It is all too common that patients terminate treatment due to these effects, leading to continued disease progression and prolonged treatment. The need to manage this condition is crucial and Lutris is doing just that with the advent of LUT014,” said Dr. Yael Gruenbaum-Cohen, DMD, PhD, Partner at aMoon Fund. “As development of LUT014 proceeds, we can foresee a paradigm shift wherein EGFRi treatment will be regularly coupled with LUT014 as a valuable adjunct. This aligns with aMoon’s mission of helping people live longer, healthier lives, and we are proud to support Lutris on their journey towards success.”

About EGFR Inhibitor-Induced Rash
EGFR is a receptor on the surface of cells which is expressed in many normal epithelial tissues, including skin. The EGFR signaling pathway is one of the key pathways that regulate growth, survival, proliferation, and differentiation of cells. B-Raf is a protein encoded by the BRAF gene and is a downstream effector component of EGFR signaling pathway. EGFR has been shown to be over-activated in various human cancers, including colorectal, lung, head and neck, urinary bladder, pancreatic and breast cancers, eliciting downstream phosphorylation and activation of the MAP Kinase pathway.

Drugs called EGFR inhibitors can block the EGFR signal responsible for cell growth. Among the various types of pharmacological therapies for cancer, EGFR inhibitors are increasingly being used both as primary therapy as well as in patients who have failed prior chemotherapy. Although effective as anti-cancer therapy leading to tumor shrinkage, EGFR inhibitors have many adverse reactions associated with their use. The majority of patients treated with EGFR inhibitors will experience adverse dermatological side effects typically manifested as a papulopustular skin rash, also known as acneiform lesions, which can impact quality of life and affect adherence to therapy. Accordingly, LUT014 has the potential to impact not only on quality of life but also on oncologic outcome.

About LUT014
LUT014 is a novel B-Raf inhibitor which is applied topically on the skin. When the B-Raf protein is mutated, as is the case in some human cancers such as melanoma, blocking this pathway leads to apoptosis of the cells and tumor shrinkage. However, when the same pathway is blocked in normal, non-mutated cells, the opposite happens: the MAPK pathway is activated, and cells start growing. This phenomenon is recognized as the paradoxical effect of B-Raf Inhibitors. LUT014 harnesses the paradoxical effect of B-Raf Inhibitors in order to reactivate the MAPK pathway and reverse the rash induced by the inhibition of this signaling pathway.

About Lutris Pharma
Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently completed a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and has successfully completed a phase 1/2 study for the treatment of radiation-induced dermatitis in breast cancer patients.

For more information, please visit www.lutris-pharma.com.

Contacts:

Lutris Pharma
Noa Shelach, Ph.D. 
Chief Executive Officer [email protected]

Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]

SOURCE Lutris Pharma

BOZEMAN, Mont., Jan. 28, 2025 — Tradeverifyd announced that it has raised an $8m Series A round led by Silicon Road VC and Bread & Butter Ventures, with participation from Acronym, Techstars, and a100x.

Tradeverifyd is redefining the intelligence standard for global enterprise supply chain risk management. The solution evolved over the prior year at mesur.io as a way to bring advanced capabilities developed for government customers to the enterprise. Tradeverifyd provides an advanced AI-driven platform designed to automatically identify and help teams mitigate supply chain risks. The solution is tailored for senior leaders in compliance and procurement aiming to protect their operations from supply chain disruptions and regulatory non-compliance.

“The challenges faced by global companies today are increasing faster than anyone thought possible. Climate change, geopolitics, and uncertainty in the markets is forcing companies to dive into the details of how their supply chains work, and where risks might arise at a level of detail that was not previously required. By partnering with our investors, we are positioning Tradeverifyd to scale to meet the demand we are seeing from the market.” said Michael Prorock, Founder and CEO.

Tradeverifyd’s exponential growth comes at a critical time when supply chain risks and compliance concerns are increasingly in the spotlight. Recent developments, such as the enforcement of the Uyghur Forced Labor Prevention Act (UFLPA) in the United States and the Supply Chain Due Diligence Act (LkSG) in Germany, as well as talks around changing tariffs and export restrictions, have heightened the need for comprehensive supply chain risk management solutions. The average annual cost of major supply interruptions to an enterprise is $228m, a number that since Covid has forced enterprises to take notice and look for solutions.

“There are more environmental and regulatory supply chain risks for anyone engaged in international trade today than ever before,” said Bread and Butter Ventures Managing Partner Brett Brohl. “It has become more costly for large companies to manage these challenges, and the consequences of failing to do so are significant. Tradeverifyd partners with corporations that need help solving these challenges, leveraging AI and a deep understanding of global supply chains.”

“Mesur.io’s Tradeverifyd addresses ‘Surety of Supply,’ one of the most important topics for manufacturers and retailers of all varieties in the United States,” added Sid Mookerji, Managing Partner at Silicon Road Ventures. “Particularly given the changing geopolitical alignments today, using mesur.io’s tech could be the difference between getting merchandise on the shelf in time for significant holidays (e.g., Christmas) and missing out on the opportunity to maximize sales. We at Silicon Road believe that Tradeverifyd will transform supply chains worldwide in the months and years to come.”

The company’s Tradeverifyd Score provides a consistent way to measure each supplier’s ability to deliver the particular products and volumes they have committed to. This includes their compliance and financial posture, as well as examining their suppliers all the way back to raw materials for both long- and short-term risks.

“Without a solid foundation in machine learning, Tradeverifyd would not be able to deliver accurate quantitative analysis,” Prorock added. “AI, enabled by LLMs, provides us the ability to effectively scale sourcing and compliance teams exponentially. Our AI agents are able to make decisions about information gathering, analysis, and recommendations on their own -and to make those decisions in a way that is informed by actual subject matter experts both in the field and within a particular organization. This means that our AI is effectively ‘personalized’ in its decision making for the needs of our customers. This is a huge breakthrough and advantage, and lets Tradeverifyd scale our data processing and analysis delivery at a level that would typically require an order of magnitude more resources. As a result, we can pass this value onto our customers.”

Tradeverifyd will use the new funding to accelerate go to market efforts across the enterprise and to improve support for supply chain leaders responding to changing regulations and compliance needs.

Tradeverifyd, with headquarters in Bozeman, MT, and strategic locations globally will serve as the go-to partner for enterprises to achieve excellence in digital supply chain transformation as they move from reactive to proactive modes of reducing supply chain risk.

For more information, visit https://tradeverifyd.com/

Media Contact: Chris Marley, [email protected]

SOURCE Mesur.io

NEW YORK, Jan. 28, 2025 – Darwin CX, a rapidly growing SaaS provider focused on transforming customer experience (CX) for publishers and subscription-based businesses, has announced a significant expansion in both funding and leadership. The company is a global leader in subscription lifecycle management solutions, helping publishers, membership organizations, and media companies seamlessly transition from print to digital. With nearly 200 clients spanning across the world, and over 7 years’ of migration expertise off various legacy platforms, Darwin CX is revolutionizing the subscription landscape.

Darwin CX recently closed $12 million in additional funding with the continued support from existing investors, First Ascent Ventures, New Era Capital Partners, and TTA Investments, who were joined by Teralys Capital, a large Canadian private fund manager. These investments are propelling the company’s expansion, enhancing its CX platform, and accelerating the development of innovative tools to support the evolving needs of subscription-based businesses.

In addition to the funding, Darwin CX is proud to announce the appointment of Tom Jenkins as Chairman of the Board. A seasoned leader and technology innovator, Jenkins is best known for his role as the former CEO and current Chairman of OpenText, a company that experienced remarkable growth under his leadership. His extensive experience in scaling tech companies and driving strategic vision makes him a perfect fit for guiding Darwin CX through its next phase of global expansion.

Tom is the former Chair of the World Wide Web Foundation, former Co-Chair of the Atlantik Bruecke, the tenth Chancellor of the University of Waterloo, as well as a former board member of Manulife, TransAlta, and Thomson Reuters Inc. Mr. Jenkins has also been appointed as an Officer of the Order of Canada and was awarded the Canadian Forces Decoration (CD), the Queen’s Diamond Jubilee Medal (QJDM) and the Knight’s Cross of the Order of Merit of the Federal Republic of Germany.

Tom’s appointment as Chairman of Darwin CX came about after CEO Liam Lynch personally reached out to Jenkins, recognizing the value that his expertise could bring to the company. “I’ve followed Tom’s work for many years and have seen first hand how his leadership can help businesses unlock their full potential,” said Lynch. “I asked Tom to join as Chairman because of his proven track record in scaling organizations and his deep understanding of the technology sector. I’m thrilled that he said yes, and I’m confident his strategic guidance will be invaluable as we continue to expand.”

Jenkins, for his part, expressed enthusiasm about his new role, highlighting the company’s strong position in the market. “Darwin CX is building something truly special by bridging the gap between the trusted offline services that publishers and member-based organisations rely on and the innovative digital solutions that are crucial for success today,” Jenkins said. “I’m excited to join the team as Chair and help steer the company toward even greater growth and innovation. The media and membership markets are ready for solutions that handle both their offline and online needs, and Darwin CX is ideally positioned to meet that demand.”

The new capital and leadership expansion come at a pivotal moment in Darwin CX’s growth journey. The funding will be used to further develop its customer experience platform, scale the Company, and enhance its product offerings, ensuring that the company remains at the forefront of the subscription economy. With a growing customer base of nearly 200 clients, Darwin CX continues to innovate in ways that support the changing needs of businesses in the subscription space.

Current investment rounds were supported by Darwin CX’s dedicated team, including Toby McCoy (Chief of Staff), Jon Soucy (CFO), TJ Cole (Senior VP – Strategy & Corporate Finance), and Chris Bedor (General Counsel).

For more information on how Darwin CX can help deliver gold-standard customer experiences for your business, please contact Cary Zel at [email protected] or Scott O’Neill at [email protected].

TAGGED WITH: Darwin CX, First Ascent Ventures, New Era Capital Partners, Teralys Capital,  Liam Lynch, Tom Jenkins

About Darwin CX
Darwin CX is a transformative SaaS platform at the leading edge of the subscription and membership economies. It helps brands accelerate acquisition and retention—and increase loyalty—through innovative and customized check-out pages, targeted audience offerings, real-time A/B testing, and best-in-class analytics. The Darwin CX platform enables clients to have complete freedom and control over customer data in order to tailor the best possible customer experiences.

About First Ascent Ventures
First Ascent Ventures is a venture capital firm that partners with high-growth, innovative companies across the SaaS and technology sectors. With a focus on scaling transformative businesses, the firm provides strategic guidance and financial support to drive success.

About New Era Capital Partners
Headquartered in Tel Aviv and Boston, New Era Capital Partners is led by industry veterans Gideon Argov, Ran Simha, and Ziv Conen. With extensive experience across North America, Europe, and Asia, New Era specializes in identifying high-potential companies at the pivotal moment when they are ready to scale. The firm focuses on supporting businesses as they expand their operations and accelerate growth.

About Teralys Capital
With $2B in assets under management, Teralys Capital is a leading private fund manager and largest innovation-focused investor in Canada. The firm supports entrepreneurs and leading technology funds who are investing in companies at every stage of growth, from early-stage start-ups to expansion and technology buy-outs. Teralys also invests internationally, helping Canadian businesses scale globally and bringing back best practices to strengthen the local ecosystem.

SOURCE Darwin CX LLC

Recent cyberattacks reveal a dangerous new trend: hackers are bypassing traditional security by targeting the automated systems that keep modern enterprises running. When state-sponsored attackers breached Microsoft and Cloudflare in early 2024, rather than going after employee passwords and accounts, the attackers compromised machine credentials instead. These machine identities — from cloud service credentials to automated system accounts — are multiplying rapidly as organizations embrace modern cloud architectures and as AI agents become a part of the daily workforce. A typical enterprise now has orders of magnitude more machine identities than human users, creating countless potential entry points for attackers.

“Hackers don’t break in; they log in,” said Itamar Apelblat, Co-Founder and CEO of Token Security. “Enterprises have done a good job securing human identities with things like multi-factor authentication, but automated systems are different. Any enterprise can pull up a list of their employees in seconds and track who has access to what. But ask them about their machine identities, and most can’t even tell you how many they have, let alone what they’re doing. When security teams identify a potential risk, figuring out who’s the human owner behind the automated process and what it’s supposed to be doing turns into a lengthy investigation that delays critical fixes and leaves systems exposed.”

Token Security solves this challenge by helping organizations discover, manage, and secure every non-human identity across their infrastructure. The platform integrates with a company’s entire technology stack, including existing identity providers, to map all machine credentials, whether they are cloud-based, SaaS solutions, or on-prem. It then automatically pinpoints who in the organization is responsible for each, and how the identity is being used. This direct connection between non-human identities and their human owners ensures swift remediation of security issues while maintaining the rapid pace of development and innovation.

“The explosion of machine identities, accelerated by agentic AI adoption and cloud-native architectures, has created an urgent need for a new approach to manage and secure non-human identities,” said Oren Yunger, Managing Partner at Notable Capital. “Token Security has emerged as the clear leader in this emerging space with the most robust and holistic product approach. Having invested in category-defining companies like HashiCorp, we recognized immediately that Token’s machine-first approach and exceptional team were building exactly what the market needed. This is evident in how quickly leading CISOs have embraced Token. The company’s remarkable traction and exceptional execution position it to reshape how enterprises secure the rapidly expanding machine identity landscape.”

About Token Security 

Token Security is a leading provider of non-human identity security solutions, specializing in automatically securing any type of non-human identity across any system and environment at scale. Token Security’s solution empowers teams to manage lifecycles, maintain secure postures, gain comprehensive visibility, and enforce least privilege — all through a centralized dashboard. Token Security was founded by 8200 security experts Itamar Apelblat and Ido Shlomo and is backed by Notable Capital, TLV Partners, SNR, and industry veterans like Kevin Patrick Mahaffey, founder of Lookout, and Shlomo Kremer, co-founder and CEO of Cato Networks.

Media Contact
Lazer Cohen
[email protected] 

Photo: https://mma.prnewswire.com/media/2606777/Token_Security.jpg

SOURCE Token Security

• Funding expands manufacturing readiness for Valley fever vaccine
• This follows Anivive’s $33MM NIAID contract for fungal vaccines
• In total, Anivive has secured over $80MM in contracts and preorders

LONG BEACH, Calif., Jan. 27, 2025 — Anivive Lifesciences, a software-driven pet health company, is pleased to announce it has secured $20MM in funding from Leonid Capital Partners (“Leonid”). Leonid is a leading investment firm focused on high-growth technology companies working in the national security industry.

“Anivive’s vision to improve and extend the lives of pets aligns perfectly with our mission to empower companies driving meaningful innovation,” said Chris Lay, Co-Founder of Leonid Capital Partners. “We’re excited to support their groundbreaking work, which has the potential to transform veterinary care for millions of pets and their families.”

The $20MM investment will help Anivive bolster its research programs, expand its manufacturing capabilities, and drive commercialization of its canine vaccine for Valley fever, the first-ever antifungal vaccine. Anivive’s direct-to-veterinarian sales platform Engage launched in early 2024 and has already processed over 9,000 orders.

This investment comes on the heels of Anivive’s recent $33M contract with the National Institutes of Health to support the development of a human vaccine against the fungus Coccidioides, which causes Valley fever. Across its pipeline, Anivive now has $80MM in preorders and commitments from industry partners.

“This partnership with Leonid is a significant milestone for Anivive,” said Dylan Balsz, CEO of Anivive. “Their capital allows us to focus on what we do best – developing cutting-edge treatments that will change the way we care for our pets.”

Anivive uses technology driven strategies to create novel, affordable healthcare solutions for pets. Through a proprietary AI platform, Anivive accelerates drug discovery and development by repurposing human treatments for veterinary use. It focuses on tackling life-threatening diseases like pet cancer, feline infectious peritonitis, systemic fungal diseases, and other emerging illnesses.

About Anivive Lifesciences

Anivive Lifesciences is a pet pharmaceutical company at the forefront of biotechnology, artificial intelligence, and veterinary medicine. Our mission is to transform veterinary healthcare by accelerating the development of novel, affordable treatments for life-threatening diseases in pets. Through our proprietary AI platform, we are pioneering first-in-class therapeutics in Oncology, Antivirals, and Antifungal Vaccines, setting new standards for innovation and excellence in the industry. To learn more, visit anivive.com.

About Leonid Capital Partners

Leonid Capital Partners invests capital into critical national security initiatives. The firm leverages its deep government and technical expertise to provide its portfolio companies with the flexible resources they need to grow their business. Learn more at leonidfinance.io.

SOURCE Anivive Lifesciences Inc.

The national advanced primary care marketplace for employers provides access in all 50 states, with 3,000 clinics located within driving distance of >80% of the U.S. population

NEW YORK, Jan. 27, 2025 — Aligned Marketplace, an advanced primary care marketplace for self-insured employers, today announced it has secured an additional $3M in seed funding from existing lead investors A* and Maverick Ventures to drive growth by taking advantage of Advanced Primary Care (APC) as a rapidly growing trend with clear employer demand. In addition, the company added numerous Fortune 500 customers in 2024 and will be presenting on its partnership with 7-Eleven to provide 7-Eleven members with nationwide access to its network of APC providers at the 2025 Conference Board Health Conference. The announcement follows recent success from Aligned Marketplace, including its initial $8 million seed funding round and official company launch, where it introduced its mission to help people find long-lasting, high quality primary care at a lower cost.

Advanced primary care focuses on delivering holistic, patient-centered care that emphasizes prevention, early intervention, and the management of chronic conditions. Unlike traditional fee-for-service models, APC integrates value-based care payment models, aligning provider incentives with improved health outcomes and cost efficiency. As cost containment continues to be a top concern for employers’ healthcare benefits strategies – employers project their healthcare costs will increase by 7.7 percent in 2025 – organizations are looking for innovative approaches to reduce costs. APC is a viable alternative to traditional primary care, and has been proven to significantly increase the quality of care, enhance patient experience, and reduce employer total medical costs by 15 percent.

“As employers grapple with rising healthcare costs, they are motivated to find innovative, value-based solutions. Advanced primary care is a win-win for employers who are looking to cut down on costs and provide access to healthcare their employees will actually use and love,” said Patrick Nelli, CEO of Aligned Marketplace. “We are excited to present the partnership with 7-Eleven and other employers this spring at multiple employer benefit conferences.”

Over the past year, Aligned Marketplace has made remarkable progress in its mission to provide high-quality, accessible primary care. The marketplace now provides access in all 50 states, with 3,000 clinics located within driving distance of greater than 80 percent of the U.S. population. Contracts with leading advanced primary care providers, including CirrusMD, Galileo, Summer Health, and more, have strengthened the ecosystem and improved member coverage. The company continues to meet diverse needs of employers nationwide by providing tools such as Population Health Analytics and Personal Health Assistants to engage members, manage high-risk populations, and reduce healthcare costs.

“As healthcare needs continue to evolve, we’re proud to partner with Aligned Marketplace to support the health and well-being of our employees,” said Dr. Scott Conard, Physician Advisor to 7-Eleven. “With access to a strong network of advanced primary care providers, we’re making it easier for our team to get the care they need when they need it.”

“This additional investment underscores our commitment to Aligned Marketplace’s industry-leading nationwide advanced primary care marketplace. We believe that advanced primary care will play a vital role in shaping the future of a healthy workforce, and we look forward to Aligned Marketplace’s continued growth and success,” said Ambar Bhattacharyya, Managing Director, Maverick Ventures.

“We are proud to invest in a company that is committed to expanding access to high quality primary care. With their recent expansions and partnerships, Aligned Marketplace is well-positioned to help improve outcomes for members and lower employers’ healthcare costs,” said Gautam Gupta, Co-Founder and General Partner, A*. 

About Aligned Marketplace
Aligned Marketplace is an advanced primary care marketplace for self-insured employers. Aligned is an easy and effective way to give employees access to advanced primary care – care that is designed to keep them healthy and proven to reduce health care costs by as much as 15 percent. With a single value-based, shared savings contract, employers see a return on investing in their employees’ improved health. By integrating seamlessly into existing health plans, Aligned Marketplace takes the pain and complexity out of offering advanced primary care. Founded in 2023 by an experienced team of health care veterans, Aligned Marketplace’s network includes more than 3,000 advanced primary care clinics in all 50 states. For more information, go to alignedmarketplace.com.

SOURCE Aligned Marketplace